TriangleNCT02576431 · CITED IN SOURCE DOCUMENTS
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2026-07-01
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Locally-advanced or metastatic malignancy with an NTRK1, NTRK2, or NTRK3 gene fusion, identified through molecular assays as routinely performed at CLIA or other similarly-certified laboratories. Subjects who have an NTRK gene fusion identified in a lab where CLIA or equivalent certification cannot be confirmed by the Sponsor at the time of consent may have been enrolled in Cohort 9 as per protocol versions 1.0 - 8.0. From protocol version 9.0: CLIA or similar certification of the lab performing the fusion assay is required. However, patients may be included after discussion with the sponsor if the lab performing the fusion assay is not CLIA or similar certified. * Subjects who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments and in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy. * Subjects must have at least one measurable lesion as defined by RECIST v1.1 (Eisenhauer et al. 2009). Subjects with solid tumors without RECIST v1.1 measurable disease (e.g., evaluable disease only) had been eligible for enrollment to Cohort 8 as per protocol versions 1.0 - 8.0, regardless of tumor type. Subjects with primary CNS tumors should meet the following criteria: 1. Have received prior treatment including radiation and/or chemotherapy, with radiation completed \> 12 weeks prior to C1D1 of therapy, as recommended or appropriate for that CNS tumor type. 2. Have ≥ 1 site of bi-dimensionally measurable disease (confirmed by magnetic resonance imaging \[MRI\] and evaluable by RANO criteria), with the size of at least one of the measurable lesions ≥ 1 cm in each dimension and noted on more than one imaging slice. 3. Imaging study performed within 28 days before enrollment. If on steroid therapy, the dose must be stable for at least 7 days immediately before and during the imaging study. 4. Must be neurologically stable based on stable neurologic exam for 7 days prior to enrollment. For subjects eligible for enrollment to bone health cohort, inclusion criterion 3 is modified as the following: 5. Subjects must have at least one lesion at baseline (measurable or non-measurable as defined by RECIST v1.1 or RANO criteria, as appropriate to tumor type). 6. Subjects with primary CNS tumors must be neurologically stable based on stable neurologic exam for 7 days prior to enrollment. * At least 18 years of age * Performance Status: Eastern Cooperative Oncology Group (ECOG) score ≤ 3. If enrolled with primary CNS tumor to be assessed by RANO, Karnofsky Performance Score (KPS) ≥ 50%. * Tumor tissue before treatment (mandatory). If neither fresh tissue can be obtained nor archival tissue is available patients might be enrolled after consultation with the sponsor. * Adequate organ function as defined by the following criteria: 1. Serum AST and serum ALT \< 2.5 x upper limit of normal (ULN), or AST and ALT \< 5 x ULN if liver function abnormalities are due to underlying malignancy 2. Total bilirubin \< 2.5 x ULN, except in the setting of biliary obstruction. Subjects with a known history of Gilberts Disease and an isolated elevation of indirect bilirubin are eligible 3. Serum creatinine \< 2.0 x ULN OR an estimated glomerular filtration rate ≥ 30 mL/minute using the Cockcroft-Gault formula: (140- age) x body weight (kg) x 0.85 (if female)/serum creatinine (mg/dL) x 72 with either result acceptable for enrollment. * Ability to comply (or for guardian to ensure compliance) with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation. * Willingness of men and women of reproductive potential to use double effective birth control methods, defined as one used by the subject and another by his/her partner, for the duration of treatment and for 1 month following study completion. * For subjects eligible for enrollment to bone health cohort only: life expectancy of at least 6 months, based on investigator assessment. Exclusion Criteria: * Investigational agent or anticancer therapy within 2 weeks prior to the planned start of larotrectinib or 5 half-lives, whichever is shorter, and without recovery of acute and/or clinically significant toxicities from that therapy. * Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK. Subjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible. * Symptomatic or unstable brain metastases. (Note: Subjects with asymptomatic brain metastases are eligible to participate in the study.) Subjects with primary CNS tumors are eligible. * Uncontrolled concurrent malignancy that would limit assessment of efficacy of larotrectinib. Allowed conditions may include, but are not limited to in situ cancers of cervix, breast, or skin, superficial bladder cancer, limited-stage prostate cancer, and basal or squamous cancers of the skin. * Active uncontrolled systemic bacterial, viral, or fungal infection CTCAE grade ≥ 2; unstable cardiovascular disease, or other systemic disease that would limit compliance with study procedures. Unstable cardiovascular disease is defined as: 1. In adults, persistently uncontrolled hypertension defined as systolic blood pressure (BP) \> 150 mmHg and/or diastolic BP \> 100 mmHg despite antihypertensive therapy. 2. Myocardial infarction within 3 months of screening. 3. Stroke within 3 months of screening. * Inability to discontinue treatment with a strong CYP3A4 inhibitor or inducer * Currently recovering from AEs/ ADRs due to previous treatments (excluding alopecia). Inclusion is only advised once the AE/ADR resolves or recovers to baseline or at least to CTCAE grade 1. * Known or suspected hypersensitivity against the active substance or any of the ingredients of the IMP. * Known history of HIV infection. All patients must be screened for HIV up to 28 days prior to study drug start using a blood test for HIV according to local regulations. * HBV or HCV infection. All patients must be screened for HBV and HCV up to 28 days prior to study drug start using the routine hepatitis virus laboratorial panel. Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBVDNA. Patients positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 1_NSCLC
- type
- EXPERIMENTAL
- description
- Patients with solid thyroid tumors harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 2_Thyroid
- type
- EXPERIMENTAL
- description
- Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 3_Sarcoma
- type
- EXPERIMENTAL
- description
- Patients with solid colorectal tumors harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 4_Colorectal
- type
- EXPERIMENTAL
- description
- Patients with solid salivary tumors harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 5_Salivary
- type
- EXPERIMENTAL
- description
- Patients with solid biliary tumors harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 6_Biliary
- type
- EXPERIMENTAL
- description
- Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 7_Primary CNS
- type
- EXPERIMENTAL
- description
- Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 8_Other tumors
- type
- EXPERIMENTAL
- description
- Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 9_Solid tumors without confirmed NTRK fusion
- type
- EXPERIMENTAL
- description
- Patients with melanoma, non secretory breast and colorectal cancer or other tumor types harboring NTRK fusions, except soft tissue sarcoma, salivary gland and thyroid cancer (arm closed)
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 10_Prospective cohort
- type
- EXPERIMENTAL
- description
- Patients with all tumor types harboring NTRK fusions, not eligible for the main prospective cohort, including patients with non-measurable disease
- intervention Names
- Drug: BAY2757556 (Larotrectinib, Vitrakvi)
- label
- Arm 11_Bone health cohort
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Arm 10_Prospective cohort
- Arm 11_Bone health cohort
- Arm 1_NSCLC
- Arm 2_Thyroid
- Arm 3_Sarcoma
- Arm 4_Colorectal
- Arm 5_Salivary
- Arm 6_Biliary
- Arm 7_Primary CNS
- Arm 8_Other tumors
- Arm 9_Solid tumors without confirmed NTRK fusion
- description
- Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
- name
- BAY2757556 (Larotrectinib, Vitrakvi)
- other Names
- LOXO-101
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 215
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Best overall response of confirmed complete response (CR) or partial response (PR) as determined by an independent radiology review committee using RECIST v1.1 or RANO criteria, as appropriate to tumor type.
- time Frame
- Up to 120 months
- secondary Outcomes
- measure
- Best overall response of confirmed CR or PR as determined by the treating Investigator using RECIST v1.1 or RANO criteria, as appropriate to tumor type
- time Frame
- Up to 120 months
- description
- Duration of response is the number of months from the start of confirmed complete response or partial response to disease progression or death. Complete response, partial response and disease progression are assessed by an independent radiology committee (IRC).
- measure
- Duration of response (DOR): determined for subjects with best overall response of confirmed CR or PR by 1) an independent radiology review committee and 2) the treating Investigator
- time Frame
- Up to 120 months
- measure
- Clinical benefit rate (CBR): best overall response of confirmed CR, PR, or stable disease lasting 16 or more weeks following the initiation of Larotrectinib
- time Frame
- Up to 120 months
- measure
- Rate of subjects that have any tumor regression as a best response, measured as shrinkage of target lesions
- time Frame
- Up to 120 months
- measure
- PFS: Number of months from initiation of larotrectinib to the earlier of disease progression or death due to any cause
- time Frame
- Up to 120 months
- measure
- Overall Survival (OS): Number of months from the initiation of larotrectinib to the date of death due to any cause.
- time Frame
- Up to 120 months
- measure
- Comparison of PFS following initiation of larotrectinib to that following the line of therapy immediately preceding larotrectinib in each subject who has received prior therapy
- time Frame
- Up to 120 months
- measure
- Number of subjects with AEs categorized by severity. (including all, serious, and those considered treatment related.)
- time Frame
- Up to 120 months
- measure
- Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration
- time Frame
- Up to 120 months
- measure
- Severity of safety-relevant changes in clinical parameters or vital signs after drug administration
- time Frame
- Up to 120 months
- description
- Concordance of prior molecular profiling that detected an NTRK fusion within the subject's tumor with the diagnostic test being evaluated by the Sponsor.
- measure
- Concordance coefficient
- time Frame
- Up to 120 months
Full study description
- brief Summary
- This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
- detailed Description
- The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults. Secondary objectives comprise the efficacy and safety of larotrectinib in different NTRK-tumor types.
Source references
- references
- citation
- Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022 Apr 29;186(6):631-643. doi: 10.1530/EJE-21-1259.
- pmid
- 35333737
- type
- BACKGROUND
- citation
- Mascarenhas L, Ollis C, Singh Y, Menachery L, Burcoveanu DI, De La Cuesta E, van Tilburg CM, Laetsch TW. Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary. Future Oncol. 2026 Aug 19:1-10. doi: 10.1080/14796694.2026.2711519. Online ahead of print.
- pmid
- 42614029
- type
- DERIVED
- citation
- Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein M. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 May;23(5):169-191. doi: 10.6004/jnccn.2025.0022.
- pmid
- 40341199
- type
- DERIVED
- citation
- Brose MS, Westphalen CB, Pan X, Bernard-Gauthier V, Kurtinecz M, Guo H, Aris V, Brett NR, Majdi A, Subbiah V, Pennell NA, Kehl KL, Drilon A. Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. JCO Precis Oncol. 2025 Apr;9:e2400500. doi: 10.1200/PO-24-00500. Epub 2025 Apr 23.
- pmid
- 40267388
- type
- DERIVED
- citation
- Mascarenhas L, DuBois SG, Albert CM, Bielack S, Orbach D, Federman N, Geoerger B, Nagasubramanian R, Zhang Y, Chisholm J, Gallego Melcon S, Goto H, Morgenstern DA, Owens C, Pappo AS, Perreault S, Schulte JH, Shukla N, Zwaan CM, Neu N, Bernard-Gauthier V, De La Cuesta E, van Tilburg CM, Laetsch TW. Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. J Clin Oncol. 2025 Apr;43(10):1180-1187. doi: 10.1200/JCO.24.00848. Epub 2025 Jan 27.
- pmid
- 39869835
- type
- DERIVED
- citation
- Hsieh CY, Hsu FL, Tsai TF. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2607-2620. doi: 10.1007/s13555-024-01229-6. Epub 2024 Jul 29.
- pmid
- 39073712
- type
- DERIVED
- citation
- Subbiah V, Burris HA 3rd, Kurzrock R. Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 2024 Jan;130(2):186-200. doi: 10.1002/cncr.35085. Epub 2023 Nov 7.
- pmid
- 37934000
- type
- DERIVED
- citation
- Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcon SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer. 2023 Dec 1;129(23):3772-3782. doi: 10.1002/cncr.35036. Epub 2023 Sep 28.
- pmid
- 37769113
- type
- DERIVED
- citation
- Bokemeyer C, Paracha N, Lassen U, Italiano A, Sullivan SD, Marian M, Brega N, Garcia-Foncillas J. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data. JCO Precis Oncol. 2023 Jan;7:e2200436. doi: 10.1200/PO.22.00436.
- pmid
- 36689698
- type
- DERIVED
- citation
- Rudzinski ER, Drilon A, Moore A, Spinosa S, Willi M, Laetsch TW. Testing methods to diagnose TRK fusion cancer - a plain language summary and patient perspective. Future Oncol. 2022 Dec;18(38):4141-4151. doi: 10.2217/fon-2022-0863. Epub 2023 Jan 6.
- pmid
- 36606522
- type
- DERIVED
- citation
- Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, Patil T, McDermott R, Raez LE, Johnson JM, Shen L, Tahara M, Ho AL, Norenberg R, Dima L, Brega N, Drilon A, Hong DS. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist. 2022 May 10;29(6):e779-88. doi: 10.1093/oncolo/oyac080. Online ahead of print.
- pmid
- 35536733
- type
- DERIVED
- citation
- Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precis Oncol. 2022 Jan;6:e2100418. doi: 10.1200/PO.21.00418.
- pmid
- 35085007
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-23c14fda90c4a1feb5d8
- requested nct id
- NCT02576431
- primary nct id
- NCT02576431
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 68c1706258e98d38c9ed48fd0c71432d06d320b05c8885ceb5fa728eadea7590
- payload sha256
- 88beb852c2df1453c3732694fbec781888d9d9bd4d14e13cd8c12d3ec805808e
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-23c14fda90c4a1feb5d8
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02576431
- occurrences
- context exact
- ref="/clinicaltrials/NCT02122913">LOXO-TRK-14001</a> (NCT02122913), <a href="/clinicaltrials/NCT02637687">SCOUT</a> (NCT02637687), and <a href="/clinicaltrials/NCT02576431">NAVIGATE</a> (NCT02576431).[<a href="#cit/section_4.3">3</a>,<a href="#cit/section_4.4">4</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810039&versio
- end
- 41720
- exact text
- NCT02576431
- start
- 41709
- context exact
- 22913">LOXO-TRK-14001</a> (NCT02122913), <a href="/clinicaltrials/NCT02637687">SCOUT</a> (NCT02637687), and <a href="/clinicaltrials/NCT02576431">NAVIGATE</a> (NCT02576431).[<a href="#cit/section_4.3">3</a>,<a href="#cit/section_4.4">4</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810039&version=HealthProfessional&la
- end
- 41747
- exact text
- NCT02576431
- start
- 41736
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/673b6b58fe51113964.html
- source file sha256
- 68c1706258e98d38c9ed48fd0c71432d06d320b05c8885ceb5fa728eadea7590
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:27.710469+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- dd1d1d1ad91100ad4c1f7e9f55ba1a72466b1757ab229115c118a2a0940b3724
- source title
- Agnostic Cancer Therapies (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 12, 2025
- datetime
- 2025-02-12T12:00:00Z
- display
- February 12, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-4c5064627c9295c4849a
- requested nct id
- NCT02576431
- primary nct id
- NCT02576431
- source kind
- fda_spl_label
- source record id
- 0e3ba6e7-af8d-4840-9409-a537a09e1263
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 19c4645285c72a93120ec35635bccbb498ad16b50eefa6006e446e57afac370b
- payload
- application numbers
- NDA210861
- NDA211710
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-4c5064627c9295c4849a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02576431
- occurrences
- context exact
- ene fusion enrolled in one of three multicenter, open-label, single-arm clinical trials: Study LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431). All patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery with significant mor
- end
- 320
- exact text
- NCT02576431
- start
- 309
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/42/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 0e3ba6e7-af8d-4840-9409-a537a09e1263
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 4f028adde96c1dc045a5281ccf403d3d7c478ae7219cdaf55133bd1b5c5e52e3
- spl effective time
- 20260522
- spl set id
- 0c8ca614-58b2-4aa4-83d3-0387a8f782fd
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5dfa5831fd1417ef86ef
- requested nct id
- NCT02576431
- primary nct id
- NCT02576431
- source kind
- fda_spl_label
- source record id
- 5b9e7961-f843-49d8-94b5-a2ce2c9efa46
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 4416983739de07958b7b64274fd341d519eece25ee205bd28a2a82c982bf2800
- payload
- application numbers
- NDA210861
- NDA211710
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5dfa5831fd1417ef86ef
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02576431
- occurrences
- context exact
- ene fusion enrolled in one of three multicenter, open-label, single-arm clinical trials: Study LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431). All patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery with significant mor
- end
- 320
- exact text
- NCT02576431
- start
- 309
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/90/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 5b9e7961-f843-49d8-94b5-a2ce2c9efa46
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- ed6532de27b99806967367f5be0d36942147b37c61bae057b6227e1d7bddc580
- spl effective time
- 20181205
- spl set id
- 9525f887-a055-4e33-8e92-898d42828cd1
Preserved source evidence · Independent clinical review pending · Not medical advice